Exploring the Contribution of Campylobacter jejuni to Post-Infectious Irritable Bowel Syndrome: A Literature Review
Source abstract
Abstract
This comprehensive review investigates the specific impact of the foodborne pathogen Campylobacter jejuni (C. jejuni) on gastrointestinal health, focusing on its connection to post-infectious irritable bowel syndrome (PI-IBS). This review examines the pathogen’s pathophysiology, clinical implications and epidemiological trends using recent research and data to highlight its prevalence and association with PI-IBS. A detailed literature analysis synthesizes current research to illuminate Campylobacter’s long-lasting effects on gut microbiota and intestinal function. It provides a detailed analysis of the literature to shed light on C. jejuni’s long-term impact on gut microbiota and intestinal function. The findings suggest the need for multifaceted prevention and treatment approaches considering individual, microbial and epidemiological factors, thus contributing to a more nuanced understanding of PI-IBS following C. jejuni infection.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Salmonella and Campylobacter epidemiology · Viral gastroenteritis research and epidemiology · Clostridium difficile and Clostridium perfringens research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Bioengineering of Animal Resources, University of Life Sciences King Michael I from Timisoara, 300645 Timisoara, Romania
Bacteriology Branch, Veterinary Sciences Division, Agri-Food and Biosciences Institute, Belfast BT4 3SD, UK
Faculty of Management and Rural Tourism, University of Life Sciences King Mihai I from Timisoara, 300645 Timisoara, Romania
Academy of Romanian Scientists, Ilfov Street, No. 3, 050044 Bucharest, Romania
Funding
King Michael I University of Life Sciences in Timisoara
References (80)
Show source-provided references
1. Omarova, S., Awad, K., Moos, V., Püning, C., Gölz, G., Schulzke, J.D., and Bücker, R. (2023). Intestinal Barrier in Post-Campylobacter jejuni Irritable Bowel Syndrome. Biomolecules, 13.10.3390/biom13030449 ↗
2. Campylobacter jejuni Increases Flagellar Expression and Adhesion of Noninvasive Escherichia coli: Effects on Enterocytic Toll-Like Receptor 4 and CXCL-8 Expression10.1128/IAI.00970-15 ↗
3. Camelina sativa oil can inhibit Campylobacter jejuni but stimulate lactic acid bacteria growth10.25083/rbl/26.2/2423.2427 ↗
4. Postinfectious Irritable Bowel Syndrome After Campylobacter Infection10.14309/ajg.0000000000000408 ↗
5. Pathophysiology of the irritable bowel syndrome—Reflections of today
6. New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter10.1016/j.trsl.2020.04.009 ↗
7. Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review10.3748/wjg.v29.i21.3241 ↗
8. Post-infectious irritable bowel syndrome following a diagnosis of traveller’s diarrhoea: A comprehensive characterization of clinical and laboratory parameters10.1093/jtm/taad030 ↗
9. Peters, S., Pascoe, B., Wu, Z., Bayliss, S.C., Zeng, X., Edwinson, A., Veerabadhran-Gurunathan, S., Jawahir, S., Calland, J.K., and Mourkas, E. (2021). Campylobacter jejuni genotypes are associated with post-infection irritable bowel syndrome in humans. Commun. Biol., 4.10.1038/s42003-021-02554-8 ↗
10. Post-infection Irritable Bowel Syndrome10.1016/j.gtc.2021.02.007 ↗
11. Human campylobacteriosis: A public health concern of global importance10.1016/j.heliyon.2019.e02814 ↗
12. Chagneau, S., Gaucher, M.-L., Thériault, W.P., Fravalo, P., and Thibodeau, A. (2023). Observations supporting hypothetical commensalism and competition between two Campylobacter jejuni strains colonizing the broiler chicken gut. Front. Microbiol., 13.10.3389/fmicb.2022.1071175 ↗
13. Bunduruș, I.A., Balta, I., Ștef, L., Ahmadi, M., Peț, I., McCleery, D., and Corcionivoschi, N. (2023). Overview of Virulence and Antibiotic Resistance in Campylobacter spp. Livestock Isolates. Antibiotics, 12.10.3390/antibiotics12020402 ↗
14. Characteristics and Risk Factors of Post-Infection Irritable Bowel Syndrome after Campylobacter enteritis10.1016/j.cgh.2020.07.033 ↗
15. Zang, X., Huang, P., Li, J., Jiao, X., and Huang, J. (2021). Genomic Relatedness, Antibiotic Resistance and Virulence Traits of Campylobacter jejuni HS19 Isolates from Cattle in China Indicate Pathogenic Potential. Front. Microbiol., 12.10.3389/fmicb.2021.783750 ↗
16. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: A randomized, clinical trial10.3389/fmed.2022.994911 ↗
17. Gut microbiota and intestinal immunity—A crosstalk in irritable bowel syndrome10.1111/imm.13749 ↗
18. Contribution of sex and gender roles to the incidence of post-infectious irritable bowel syndrome in a prospective study10.1038/s41598-023-45300-2 ↗
19. Long-term Clinical Course of Post-infectious Irritable Bowel Syndrome after Shigellosis: A 10-year Follow-up Study10.5056/jnm15157 ↗
20. Post-Infectious Sequelae of Travelers’ Diarrhea: Reactive Arthritis, Guillain-Barré Syndrome, and Irritable Bowel Syndrome10.1007/s40475-016-0080-4 ↗
21. Balmus, I.-M., Ilie, O.-D., Ciobica, A., Cojocariu, R.-O., Stanciu, C., Trifan, A., Cimpeanu, M., Cimpeanu, C., and Gorgan, L. (2020). Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise—Searching for Gap Fillers in the Oxidative Stress Way of Thinking. Medicina, 56.10.3390/medicina56010038 ↗
22. Post-infectious irritable bowel syndrome after a laboratory-proven enteritis
23. Post-infectious irritable bowel syndrome after intercontinental travel: A prospective multicentre study10.1093/jtm/taad101 ↗
24. Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis10.1136/gutjnl-2015-309460 ↗
25. Systematic review with meta-analyses: Does the pathogen matter in post-infectious irritable bowel syndrome?10.1080/00365521.2019.1607897 ↗
26. Campylobacter jejuni and associated immune mechanisms: Short-term effects and long-term implications for infants in low-income countries10.1097/QCO.0000000000000364 ↗
27. Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome10.1053/j.gastro.2018.07.011 ↗
28. Campylobacter infection and the link with Irritable Bowel Syndrome: On the pathway towards a causal association10.1093/femspd/ftac003 ↗
29. Idiopathic colitis in rhesus macaques is associated with dysbiosis, abundant enterochromaffin cells and altered T-cell cytokine expression10.1177/0300985818780449 ↗
30. Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review10.3390/gidisord5040043 ↗
31. Hong, G., Davies, C., Omole, Z., Liaw, J., Grabowska, A.D., Canonico, B., Corcionivoschi, N., Wren, B.W., Dorrell, N., and Elmi, A. (2023). Campylobacter jejuni modulates reactive oxygen species production and NADPH oxidase 1 expression in human intestinal epithelial cells. Cell. Microbiol., 2023.10.1155/2023/3286330 ↗
32. Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis10.1053/j.gastro.2009.12.049 ↗
33. Mixtures of natural antimicrobials can reduce Campylobacter jejuni, Salmonella enterica and Clostridium perfringens infections and cellular inflammatory response in MDCK cells10.1186/s13099-021-00433-5 ↗
34. Anti-Campylobacter probiotics: Latest mechanistic insights10.1089/fpd.2022.0039 ↗
35. Backert, S. (2021). Fighting Campylobacter Infections: Towards a One Health Approach, Springer Nature.10.1007/978-3-030-65481-8 ↗
36. Campylobacter jejuni: Targeting host cells, adhesion, invasion, and survival10.1007/s00253-023-12456-w ↗
37. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS10.1136/gutjnl-2018-317416 ↗
38. Porter, C.K., Choi, D., Cash, B., Pimentel, M., Murray, J., May, L., and Riddle, M.S. (2013). Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. BMC Gastroenterol., 13.10.1186/1471-230X-13-46 ↗
39. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis10.1053/j.gastro.2016.12.039 ↗
40. Callahan, S.M., Dolislager, C.G., and Johnson, J.G. (2021). The Host Cellular Immune Response to Infection by Campylobacter spp. and Its Role in Disease. Infect. Immun., 89.10.1128/IAI.00116-21 ↗
41. Post-infectious Irritable Bowel Syndrome: A Narrative Review10.15171/mejdd.2019.130 ↗
42. Dong, L.W., Sun, X.N., Ma, Z.C., Fu, J., Liu, F.J., Huang, B.L., Liang, D.C., Sun, D.M., and Lan, C. (2021). Increased Vδ1γδT cells predominantly contributed to IL-17 production in the development of adult human post-infectious irritable bowel syndrome. BMC Gastroenterol., 21.10.1186/s12876-021-01722-8 ↗
43. Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection--an observation in a small case control study10.3349/ymj.2010.51.1.45 ↗
44. Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome10.1111/j.1440-1746.2011.07046.x ↗
45. Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome10.1111/jtm.12218 ↗
46. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome10.1136/gut.52.4.523 ↗
47. Pathogenic Factors in Postinfectious Irritable Bowel Syndrome-An Update
48. Awad, K., Barmeyer, C., Bojarski, C., Nagel, O., Lee, I.-F.M., Schweiger, M.R., Schulzke, J.-D., and Bücker, R. (2023). Epithelial Barrier Dysfunction in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) via Downregulation of Claudin-1. Cells, 12.10.3390/cells12242846 ↗
49. Susceptibility to Campylobacter infection is associated with the species composition of the human fecal microbiota10.1128/mBio.01212-14 ↗
50. Role of the gut microbiota in health and chronic gastrointestinal disease: Understanding a hidden metabolic organ10.1177/1756283X13482996 ↗
51. Human microbiome: An academic update on human body site specific surveillance and its possible role10.1007/s00203-020-01931-x ↗
52. Gut microbiota functions: Metabolism of nutrients and other food components10.1007/s00394-017-1445-8 ↗
53. Gut microbiota, metabolites and host immunity10.1038/nri.2016.42 ↗
54. Inflammation and colorectal cancer, when microbiota-host mutualism breaks10.3748/wjg.v20.i4.908 ↗
55. Problems with the concept of gut microbiota dysbiosis10.1111/1751-7915.13479 ↗
56. Sharafutdinov, I., Tegtmeyer, N., Müsken, M., and Backert, S. (2022). Campylobacter jejuni Serine Protease HtrA Induces Paracellular Transmigration of Microbiota across Polarized Intestinal Epithelial Cells. Biomolecules, 12.10.3390/biom12040521 ↗
57. Napolitano, M., Fasulo, E., Ungaro, F., Massimino, L., Sinagra, E., Danese, S., and Mandarino, F.V. (2023). Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications. Microorganisms, 11.10.3390/microorganisms11102369 ↗
58. Gabbert, A.D., Mydosh, J.L., Talukdar, P.K., Gloss, L.M., McDermott, J.E., Cooper, K.K., Clair, G.C., and Konkel, M.E. (2023). The Missing Pieces: The Role of Secretion Systems in Campylobacter jejuni Virulence. Biomolecules, 13.10.3390/biom13010135 ↗
59. Byale, A., and Grover, M. (2024). Understanding Postinfection Irritable Bowel Syndrome. Hepatology, in press.
60. Butucel, E., Balta, I., McCleery, D., Marcu, A., Stef, D., Pet, I., Callaway, T., Stef, L., and Corcionivoschi, N. (2023). The Prebiotic Effect of an Organic Acid Mixture on Faecalibacterium prausnitzii Metabolism and Its Anti-Pathogenic Role against Vibrio parahaemolyticus in Shrimp. Biology, 12.10.3390/biology12010057 ↗
61. The emerging roles of bacterial proteases in intestinal diseases10.1080/19490976.2023.2181922 ↗
62. Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome10.3748/wjg.v24.i3.338 ↗
63. Expression of Toll-like Receptors, Pro-, and Anti-inflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis10.5056/jnm18130 ↗
64. Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery10.1136/gutjnl-2021-326828 ↗
65. Postinfection Irritable Bowel Syndrome10.5009/gnl210208 ↗
66. Faecal microbiota composition and host–microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome10.1136/gutjnl-2013-305994 ↗
67. Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome10.1016/j.cgh.2023.02.014 ↗
68. Chong, P.P., Chin, V.K., Looi, C.Y., Wong, W.F., Madhavan, P., and Yong, V.C. (2019). Corrigendum: The Microbiome and Irritable Bowel Syndrome—A Review on the Pathophysiology, Current Research and Future Therapy. Front. Microbiol., 10.10.3389/fmicb.2019.01870 ↗
69. Postinfectious irritable bowel syndrome—A meta-analysis10.1111/j.1572-0241.2006.00654.x ↗
70. Mousavi, S., Bereswill, S., and Heimesaat, M.M. (2021). Fighting Campylobacter Infections: Towards a One Health Approach, Springer Nature.
71. Heimesaat, M.M., Backert, S., Alter, T., and Bereswill, S. (2023). Molecular Targets in Campylobacter Infections. Biomolecules, 13.10.3390/biom13030409 ↗
72. Heimesaat, M.M., Backert, S., Alter, T., and Bereswill, S. (2021). Fighting Campylobacter Infections: Towards a One Health Approach, Springer Nature.
73. A secreted sirtuin from Campylobacter jejuni contributes to neutrophil activation and intestinal inflammation during infection10.1126/sciadv.ade2693 ↗
74. Tegtmeyer, N., Sharafutdinov, I., Harrer, A., Soltan Esmaeili, D., Linz, B., and Backert, S. (2021). Fighting Campylobacter Infections: Towards a One Health Approach, Springer Nature.
75. Balta, I., Linton, M., Pinkerton, L., Kelly, C., Ward, P., Stef, L., Pet, I., Horablaga, A., Gundogdu, O., and Corcionivoschi, N. (2021). The effect of natural antimicrobials on the Campylobacter coli T6SS+/− during in vitro infection assays and on their ability to adhere to chicken skin and carcasses. Int. J. Food Microbiol., 338.10.1016/j.ijfoodmicro.2020.108998 ↗
76. Campylobacter jejuni transcriptional and genetic adaptation during human infection10.1038/s41564-018-0133-7 ↗
77. Cui, J., Duizer, C., Bouwman, L.I., van Rooijen, K.S., Voogdt, C.G.P., van Putten, J.P.M., and de Zoete, M.R. (2021). The ALPK1 pathway drives the inflammatory response to Campylobacter jejuni in human intestinal epithelial cells. PLoS Pathog., 17.10.1371/journal.ppat.1009787 ↗
78. Sharafutdinov, I., Tegtmeyer, N., Rohde, M., Olofsson, A., Rehman, Z.u., Arnqvist, A., and Backert, S. (2024). Campylobacter jejuni Surface-Bound Protease HtrA, but Not the Secreted Protease nor Protease in Shed Membrane Vesicles, Disrupts Epithelial Cell-to-Cell Junctions. Cells, 13.10.3390/cells13030224 ↗
79. Knowledge gaps in control of Campylobacter for prevention of campylobacteriosis10.1111/tbed.12870 ↗
80. Bandick, R., Busmann, L.V., Mousavi, S., Shayya, N.W., Piwowarski, J.P., Granica, S., Melzig, M.F., Bereswill, S., and Heimesaat, M.M. (2023). Therapeutic Effects of Oral Application of Menthol and Extracts from Tormentil (Potentilla erecta), Raspberry Leaves (Rubus idaeus), and Loosestrife (Lythrum salicaria) during Acute Murine Campylobacteriosis. Pharmaceutics, 15.10.3390/pharmaceutics15102410 ↗